AMGN vs BMY
Amgen and Bristol Myers Squibb, both Healthcare
Amgen is the larger company at $182B against $110B. On trailing earnings BMY is the cheaper of the two at a P/E of 14.9 against 27.4, a gap that is only a bargain if the two are growing at similar rates. Over the past year AMGN returned +59% against +56% for BMY.
| Figure | AMGN | BMY |
|---|---|---|
| Last close | $440 | $67.58 |
| Market cap | $182B | $110B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.4 | 14.9 |
| Dividend yield | 2.2% | 3.7% |
| 1-year return | +59% | +56% |
| 5-year return | +113% | +21% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Amgen
Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.
Bristol Myers Squibb
Revenue of $13B in Q2 2026, net income $3.3B. Its largest reported line is Eliquis, 34% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.